Doc Code: TRACK1.REQ
`DocumentDescription: TrackOne Request
`
`PTO/AIA/424 (04-14)
`
`CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION
`UNDER 37 CFR 1.102(e) (Page 1 of1)
`
`Osteoclast Inhibitors of Knee Conditions
`
`APPLICANT HEREBYCERTIFIES THE FOLLOWING AND REQUESTSPRIORITIZED EXAMINATION FOR
`THE ABOVE-IDENTIFIED APPLICATION.
`
`1. The processing fee set forth in 37 CFR 1.17(i)(1) and the prioritized examination fee set forth in
`37 CFR 1.17(c) have been filed with the request. The publication fee requirement is met
`because that fee, set forth in 37 CFR 1.18(d), is currently $0. The basic filing fee, search fee,
`and examination fee are filed with the request or have been already been paid.
`| understand
`that any required excessclaims fees or application size fee must be paid for the application.
`
`| understand that the application may not contain, or be amendedto contain, more than four
`independentclaims, morethan thirty total claims, or any multiple dependent claims, and that
`any request for an extension of time will cause an outstanding Track | request to be dismissed.
`
`3. The applicable box is checked below:
`
`Original Application (Track One)
`
`- Prioritized Examination under §
`
`i.
`
`(a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a).
`This certification and requestis being filed with the utility application via EFS-Web.
`
`(b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111(a).
`This certification and requestis being filed with the plant application in paper.
`
`An executed inventor’s oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each
`inventor, or the application data sheet meeting the conditions specified in 37 CFR 1.53(f\(3)(i) is
`filed with the application.
`
`forms are submitted.
`
`A requestfor continued examination has beenfiled with, or prior to, this form.
`If the application is a utility application, this certification and requestis being filed via EFS-Web.
`ili. The application is an original nonprovisionalutility application filed under 35 U.S.C. 111(a), oris
`a national stage entry under 35 U.S.C. 371.
`iv. This certification and requestis being filed prior to the mailing of a first Office action responsive
`to the request for continued examination.
`No prior request for continued examination has been granted prioritized examination status
`under 37 CFR 1.102(e)(2).
`
`signature /Brent A. Johnson/
`pate 22 July 2016
`
`Name
`Brent A. Johnson
`Practitioner
`51851
`(Print/Typed)
`Registration Number
`
`This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications.
`Note:
`Submit muitiple forms if more than one signature is required. *
`
`*Total of
`
`1
`
`Grun. Exh. 1017
`PGR for U.S. Patent No. 10,052,338
`
`1
`
`Grün. Exh. 1017
`PGR for U.S. Patent No. 10,052,338
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of
`the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2)
`furnishing of the information solicited is voluntary; and (8) the principal purpose for which the information is used by the
`U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or
`patent.
`If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to
`process and/or examine your submission, which mayresult in termination of proceedings or abandonmentof the
`application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
`be disclosed to the Department of Justice to determine whether disclosure of these records is required by the
`Freedom ofInformation Act.
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from
`the Member with respect to the subject matter of the record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information shall be required to comply
`with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuantto the Atomic Energy Act (42 U.S.C.
`218(c)).
`A record from this system of records may bedisclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSAaspart of that agency’s
`responsibility to recommend improvements in records managementpractices and programs, under authority of
`44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing
`inspection of recordsfor this purpose, and any other relevant(i.e., GSA or Commerce)directive. Such
`disclosure shall not be used to make determinations about individuals.
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a
`record may bedisclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record
`wasfiled in an application which became abandonedor in which the proceedings were terminated and which
`application is referenced by either a published application, an application open to public inspection or an issued
`patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes awareof a violation or potential violation of law or regulation.
`
`2
`
`

`

`
`
`PTOIALAION (06-12)
`Approved for use through 04/31/2014, OMB 0551-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no sersars are required to respond to @ collection of information uniess f displays a vaild OMB contro! number.
`
`i
`
`DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET (37 CFR 1.76}
`
`Titeof|OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS
`nvention
`
`en previously filed. Use an additional PTO/AIA/O1 formfor each additional inventor, This coflection of information is required by 35 U.S.C. 115 and 3? CFR 1.83. The information {s required to obtain ar retain a benefit by ihe public whichis to file (and
`
`f
`Patitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may
`coriribute to identily theil. Personal infomation such as social security numbers, bank account numbers, or credit card numbers |
`{ather than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO}
`to support a petition or an application.
`if this type of personal information is Included in documents submitted to the USPTO,
`5
`petitioners/applicants should consider redacting such personal information from the documents before submitting them io the
`USPTO. Pelitioner/applicant is advised that the recard of a patent application is available to the public after publication of the
`application (unless a non-publication request in compliance with 37 CFR 1.213{a) is made in the application) or issuance of a
`‘patent. Furthermore, the record from an abandonedapplicationmay also be available to the public ifthe application is
`referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and creditcard authorization forms
`TO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.
`
`| As the below named inventor, | hereby declare that:
`
`This declaration
`is directed to:
`
`I
`
`[gl
`ei
`[|
`
`+.
`‘
`;
`The atlached application, or
`United States agplication or PCTinternational application number
`filed on
`
`The above-identified application was made or authorized to be made by me.
`
`| believe that | am the original inventor or an Griginal joint inventor of a claimed invention in the appiication.
`
`i hereby acknowledge that any willful false staternent made in this declaration is punishable under 18 U.S.C. 1001
`by fine or imprisonment of not more than five (5) years, or both.
`
`WARNING:
`
`LEGAL NAME OF INVENTOR
`
`Inventor
`
`Signature:
`
`Herriot Tabuteau
`
`/Herriot Tabuteau/
`
`Date (Optional:
`
`‘icte: An application data sheet (PTO/S8/14 or equivalent), including naming the entire inventive entity, must accompanythis form or must have
`
`is governed by 35 U.S.C. 122 and 37 CFR 1.14 and 1.14. This collection is estimated to take t minute to
`by the USPTO to process) an application. Confidentiality
`
`complete, including gathering, preparing, and subrnitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any
`
`
`comments on the amount of time you require to complete this form and/or suggestionsfor reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O. Gox 1450, Alexandria, VA 22313-1456. DO NOT SEND FEES OR COMPLETED FORMS TO
`THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22343-1460,
`ffyou need assistance in completing the form, call 1-800-PTO-9799 and select option 2
`
`3
`
`

`

`PTOUAIIBL 81H
`Approved for use MhmughOU/S1/2014.. OMS C6St-O0S2
`US. DEPARTMENT OF COMMERCE
`U.S: Patent and Yrademark Office:
`Underthe Pagerank Reduction Atot TOSS, ne péisons ans requirest$5 iespond tea collention af idormation unless Realaptayea Valid OMB control nbsribes.
`DECLARATION (37 GER 4.63) FOR UTILITY OR DESIGN APPLICATION USING AN
`APPLICATION DATA SHEET(87 CFR 1.78}
`| OST:EOCLAST INHIBITORS FOR KNEE CONDITIONS
`
`| invention |
`
`\
`“Tite of
`
`i As thebelow named inventor, | hereby declarethat
`Ths declaration
`Js directed fa’ The attached application,‘or
`i] United States application or POT international application nuraber
`filed or
`
`f The alicve-identiied appication was meds or authorized to be made by:me.
`
`Et beliave that lamihe original inventor-or anh origiial joint iventor of a claiméd invention in the-application
`
`} hereby acknowledge chat any will false statement made.in this deniaration iepunishable tinder 16 W.8:C. 1007
`:
`Lby fine-or imprisonment of not more than five (5) yeurs, or both.
`
`WARNING:
`(otherthor:a.eWeckor opal card authentzation form PTO2838 dubinited for payment purposes)|Is newer roquired|by theUSPTO!
`io support a pelifion or.an application.
`ifthis tyne of persénal.information is included in-documents subraitied tothe USPTO,
`patitioners/appiicanis should consider redacting such personal inforraation fromthe documents. before submitting them to.the
`USPTO. Peliionerfapplicant|ig advised that the record of a patent application is avaliable te the oublicafter publication ofthe
`appligation (unless a non-publication request in compliance with 9? CPR 7.213{a)is madein the application} or issuance. of a
`patent. Furtheimore, ine record from an abandoned application may also be available to the publicifthe application is
`referenced: ine:publishsdapplicationoran lesuad patent (see 37 CER 114). Checks and credit carl authorization forms
`PTO-2038 aubmitied for payment purposes are not retained in the application file end therefore are not publicly avaliable,
`
`‘been previously fad: Use an addtional PTOAMANT forn for each additonal:inventor:
`
`LEGAL NAME OF INVENTOR
`
`invenice, GraemeJones.
`Signature:
`
`a ate (Optional)STAYee
`
`i NotesAn application datz: sheet rrCVSAN4 of equivalent},including naming ihe -antike inventive entity, musl aecompanythis form oFmustnave
`
`“The Coke a infornedion:ig. regured y38 US.18 ad 37 CFR 4.83. Theinformation ta required40 htake orzetaina benefit by the public which is fo file(and
`bythe USPTOt process) anappiication, Contdentiaiiy is govemed by 45 U.S.C. 122 and 37 GER 1.74and 4.14. This collention ie wetinaied to wake tenuis to
`nomplets, lcludinig gating, preparing, and submbting ihecovpieied applzeiion formfathe USPTO. Timewil vary depending LipaBes Individiial case. An¥
`Soriments on ihe amiaunt ef tine you require to compéate thie form and/or suggestions for reducing this -burten, should be seci te the Chist information Officer, U8.
`Patert.and Tracenaerk OMox, U.S. Oerariment of Commence, P.O, Box 1480) Alevandtig, ‘Va 22343-1450,00 MOT SEND FEESOR COMPLETED FORMS TG
`THIS ADDRESS, SEND TO:Comminsionarfor Patents, P.O. Box 1498, Alexandria, vA.22393-1480,
`iPyou ned aasisiincein completing tae tomy, call 1-00-P7.0198 andselectoption 2:
`
`
`
`
`
`
`
`4
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`icati
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`The application data sheetis part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arrangedin a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document maybe printed and included in a paperfiled application.
`
`Secrecy Order 37 CFR5.2:
`
`Oo Portionsorall of the application associated with this Application Data Sheet mayfall under a Secrecy Order pursuantto
`
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may notbefiled electronically.)
`
`Inventor Information:
`
`
`
`Family Name
`a
`ResidenceInformation (Select One)
`@ US Residency
`Non US Residency
`Active US Military Service
`
`|city|| State/Province [Ny|Country of Residencd
`
`Middle Name
`
`
`
`Mailing Addressof Inventor:
`
`Address1—([SBemivarRen
`Address?|
`
`
`|city|| lew York State/Province
`
`[PosiGode[JORteatsps
`enebe
`Legal Name
`
`
`[Pret]GivenName«Middle_—_———~idFamilyNameiSiName
`
`feedT
`Active US Military Service
`
`Mailing Addressof Inventor:
`
`
`
`aA
`
`ddress?|ovepeotst_
`rey[for SSCSCSCSCSCS~*diSeProvinceSS
`rPostalGode[pmo———S—~idoumyis
`All
`Inventors Must Be Listed - Additional
`Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`Add
`
`Correspondence Information:
`
`EFS Web 2.2.12
`
`5
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`
`Attorney Docket Number|1958603.00192
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Enter either Customer Number or complete the CorrespondenceInformation section below.
`For further information see 37 CFR 1.33(a).
`
`[_] An Addressis being provided for the correspondenceInformation of this application.
`Customer Number
`fi 5200
`Email Address
`| ocPatents@klgates.com
`
`Add Email
`
`Remove Email
`
`
`
`
`
`
`|1958603.00192
`Small Entity Status Claimed
`Attorney Docket Number}
`|emoveona
`Application Type
`Subject Matter pay
`Total Numberof Drawing Sheets(if any) 4 Suggested Figure for Publication (if any) ||
`Filing By Reference:
`
`Only complete this section whenfiling an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this sectionif
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information” and “Foreign Priority Information’).
`
`Application Information:
`
`
`Title of the Invention
`
`OsteoclastInhibitors for Knee Conditions
`
`For the purposesofa filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previouslyfiled application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`i
`
`Application numberof the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country
`
`Po
`
`Publication Information:
`
`
` Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request Not to Publish. | hereby requestthat the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`
`publication at eighteen months afterfiling.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a powerof attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`
`Numberwill be used for the Representative Information during processing.
`
`
`
`Please Select One:
`
`@ Customer Number
`
`US Patent Practitioner © Limited Recognition (37 CFR 11.9)
`
`Customer Number
`
`EFS Web 2.2.12
`
`6
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Attorney Docket Number|1958603.00192
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Osteoclast Inhibitors for Knee Conditions
`
`Title of Invention
`
`
`
`
`Continuity Type
`| ontinuation in part of
`
`Prior Application
`
`
`
`
`
`
`
`
`
`Domestic Benefit/National Stage Information:
`
`
`
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate
`
`
`National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes
`the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the “Application Number”field blank.
`
`
`
`
`Filing or 371(c) Date
`
`
`Application Number
`Continuity Type
`Prior Application Number
`(YYYY-MM-DD)
`
`
`
`aorrn
`are
`
`
`
`
`Application
`PriorApplication
`FilingDate aDate
`
`|jraro67224
`“mammaEtaso
`pa015-01-23
`|E211257
`re015-12-15
`
`
`
`
`Filing or 371(c) Date
`
` Prior Application Number
`Application Number
`(YYYY-MM-DD)
`
`
`
`
`2014-11-07
`| 41604524
`| 14/536526
`
`
`
`Issue Date
`Filing Date
`_
`Application
`(YYYY-MM-DD)
`Patent Number
`(YYYY-MM-DD)
`Continuity Type
`Number
`
`
`
`|[14/536526 | ontinuation in part of [+] [14/446184 2014-07-29 p015-04-14
`
`
`
`
`
`
`
`Remove
`
`
`
`
`
`Prior Application
`Filing Date
`Issue Date
`Application
`.
`
`
`Number
`Continuity Type
`(YYYY-MM-DD)
`Patent Number
`(YYYY-MM-DD)
`Number
`
`14/446184
`Divisionofeek14/288716 feet
`6835650
`po14-09-16
`
`
`
`
`Prior Application Status||
`
`
`
`
`Filing or 371(c) Date
`Application Number
`Prior Application Number
`(YYYY-MM-DD)
`
`| 4/288716
`-| 61/933608
`2014-01-30
`
`
`
`
`
`
`
`Application
`a
`Prior Application
`Filing Date
`Issue Date
`
`
`Number
`Continuity Type
`Number
`(YYYY-MM-DD)
`Patent Number
`(YYYY-MM-DD)
`
`por4-05-15 9034889 po15-05-19
`14/536526
`
`
`
`
`
`
`
`
`
`PriorApplication Status Paeved
`Remove
`
`
`
`
`
`
`Prior Application
`Filing Date
`Issue Date
`Application
`
`
`
`|141279229 |Continuationof|_|+]j14/063979 pa013-10-25 8802658 bo14-08-12
`
`
`
`Continuity Type
`| laims benefit of provisional
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EFS Web 2.2.12
`
`7
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Attorney Docket Number|1958603.00192
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Application Number
`
`
`| 4/063979
`
`Continuity Type
`
`| ontinuation in part of
`
`
`
`
`
`
`
` Remove
`
`Filing or 371(c) Date
`
`
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`
`2013-05-14
`-| 13/894274
`
`
`
`
`
`Filing or 371(c) Date
`
`(YYYY-MM-DD)
`Prior Application Number
`Continuity Type
`Application Number
`2013-03-20
`-| 61/803721
`| laims benefit of provisional
`| 3/894274
`
`
`
`
`
`Prior Application Status [Exvired
`Remove
`
`
`
`Filing or 371(c) Date
`
`
`
`Application Number
`Continuity Type
`(YYYY-MM-DD)
`Prior Application Number
`
`
`
`
`
`
`| 3/894274 |*] 61/767647|2013-02-21| laims benefit of provisional
`
`
`
`Filing or 371(c) Date
`
`
`
`Continuity Type
`Application Number
`(YYYY-MM-DD)
`Prior Application Number
`
`
`
`
`| 61/76/7676
`| 3/894274
`| laims benefit of provisional
`2013-02-21
`
`
`
`
`
`
`
`Filing or 371(c) Date
`
`
`Prior Application Number
`(YYYY-MM-DD)
`
`
`-| 61/764563
`2013-02-14
`
`
`
`
`
`
`Filing or 371(c) Date
`
`(YYYY-MM-DD)
`2013-02-07
`
`Remove
`
`Filing or 371(c) Date
`
`(YYYY-MM-DD)
`Prior Application Number
`
`
`2012-06-05
`-| 61/655541
`
`
`
`
`
`
`
`
`
`Filing or 371(c) Date
`
`
`
`Application Number
`Continuity Type
`(YYYY-MM-DD)
`
`
`
`
`
`| 3/894274 |*]| 61/655527|2012-06-05| laims benefit of provisional
`
`
`
`
`
`Prior Application Number
`Continuity Type
`Application Number
`-| 61/762225
`| laims benefit of provisional
`| 3/894274
`Prior Application Status [Exired
`
`Application Number
`
`Continuity Type
`
`
`| 3/894274
`
`| laims benefit of provisional
`
`
`
`
`Application Number
`| 3/894274
`
`Continuity Type
`| laims benefit of provisional
`
`Prior Application Number
`
`Application Number
`| 34894274
`
`EFS Web 2.2.12
`
`Filing or 371(c) Date
`
`Prior Application Number
`(YYYY-MM-DD)
`Continuity Type
`| laims benefit of provisional
`| 61/654383
`2012-06-01
`
`8
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Attorney Docket Number|1958603.00192
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Application Number
`
`
`| 3/894274
`
`Continuity Type
`
`| laims benefit of provisional
`
`
`
`
`
` Remove
`
`Filing or 371(c) Date
`
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`
`
`-| 61/654292
`2012-06-01
`
`
`
`
`
`Filing or 371(c) Date
`
`(YYYY-MM-DD)
`Prior Application Number
`Continuity Type
`Application Number
`2012-05-15
`-| 61/647478
`| laims benefit of provisional
`| 3/894274
`
`
`
`
`
`Prior Application Status [Exvired
`Remove
`
`
`
`Filing or 371(c) Date
`
`
`
`
`
`Continuity Type
`Application Number
`(YYYY-MM-DD)
`Prior Application Number
`
`
`
`
`| 3/894274 |*] 61/646538|2012-05-14| laims benefit of provisional
`
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. Whenpriority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX)! the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g){1).
`
`Addbutton.
`
`Application Number
`
`|
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`
`Remove
`Access Code (if applicable)
`
`
`
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effectivefiling date on or after March
`16, 2013.
`NOTE: Byproviding this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined underthefirst inventorto file provisions of the AIA.
`
`
`
`
`
`
`EFS Web 2.2.12
`
`9
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Attorney Docket Number|1958603.00192
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`application in accordance with 37 CFR 1.14.
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written
`authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see
`paragraph Ain subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant
`application (see paragraph B in subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an
`application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind
`authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`
`A. Priority Document Exchange (PDX)- Unless box A in subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office
`(JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People’s Republic of
`China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office
`participating with the USPTOin a bilateral or multilateral priority document exchange agreementin which a foreign
`application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed
`andits related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the
`instant application and its related bibliographic data, and (3) the date offiling of this Authorization. See 37 CFR 1.14(h)
`(1).
`
`B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked,
`the undersigned hereby grants the USPTO authority to provide the EPO accessto the bibliographic data and search
`results from the instant patent application when a European patent application claiming priority to the instant patent
`application is filed. See 37 CFR 1.14(h)(2).
`
`The applicant is reminded that the EPO’s Rule 141(1) EPC (European Patent Convention) requires applicants to submit a
`copy of search results from the instant application without delay in a European patent application that claims priority to
`the instant application.
`
`2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s}
`
`A. Applicant DOES NOT authorize the USPTOto permit a participating foreign IP office access to the instant
`|] application-as-filed.
`If this box is checked, the USPTOwill not be providing a participating foreign IP office with
`any documents and information identified in subsection 1A above.
`
`[_]
`
`B. Applicant DOES NOT authorize the USPTOto transmit to the EPO any search results from the instant patent
`application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant
`application.
`NOTE: Oncethe application has published or is otherwise publicly available, the USPTO may provide access to the
`
`EFS Web 2.2.12
`
`10
`
`10
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`
`Attorney Docket Number|1958603.00192
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Applicant Information:
`
`
`Providing assignmentinformation in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`
`4
`Applicant
`If the applicantis the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`Theinformation to be provided in this section is the name and addressof the legal representative whois the applicant under 37 CFR
`1.43; or the name and addressof the assignee, person to whom the inventoris under an obligation to assign the invention, or person
`who otherwise showssufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventoris obligated to assign, or person who otherwise showssufficient
`proprietary interest) together with one or morejoint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`Legal Representative under 35 U.S.C. 117
`
`Joint Inventor
`
`Person to whemthe inventoris obligated to assign.
`
`Person who showssufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`
`
`
`
`
`Nameof the Deceased or Legally Incapacitated Inventor:
`
`If the Applicant is an Organization check here.
`
`x
`
`Organization Name
`
`: ANTECIP BIOVENTURESII LLC
`
`Mailing Address Information For Applicant:
`
`Address 1
`
`Address 2
`
`630 Fifth Avenue, Suite 2000
`
`
`
`Email Address
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`AssigneeInformation including Non-Applicant Assignee Information:
`
`
`Providing assignmentinformation in this section does not substitute for compliance with any requirementof part 3 ofTitle
`37 of CFR to have an assignment recorded by the Office.
`
`
`EFS Web 2.2.12
`
`11
`
`11
`
`

`

`PTO/AIA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Attorney Docket Number|1958603.00192
`Application Data